Displaying publications 1 - 20 of 35 in total

Abstract:
Sort:
  1. Non-secretory multiple myeloma with diagnostic challenges
    Hamidah NH, Azma RZ, Ezalia E, Das S, Umar NA, Swaminathan M, et al.
    Clin Ter, 2010;161(5):445-8.
    PMID: 20949241
    Non-secretory multiple myeloma (NSMM) is a rare variant of the classic form of multiple myeloma (MM). In NSMM, no monoclonal gammopathy can be detected in serum or urine by conventional techniques, making the diagnosis more difficult. We describe a 71-year-old man who had been diagnosed and treated for granulocytic sarcoma one year prior to his recent problems of progressive low-back pain of two months duration. Skeletal X-rays showed diffuse osteolytic lesions with multiple pathological fractures but there was no monoclonal gammopathy in the serum or urine. The biopsy of the lytic lesion on the upper part of the femur showed infiltration by abnormal plasma cells. A diagnosis of NSMM was made and he was treated with chemotherapy. The early diagnostic difficulty and the challenges faced regarding the case are discussed.
    Matched MeSH terms: Multiple Myeloma/diagnosis*
  2. Fulltext Good anatomical outcome of orbital plasmacytoma following chemo-radiotherapy
    Aimy Mastura, Z. Y., Othmaliza, O., Khairunisa, A. A., Norshamsiah, M. D.
    Medicine & Health, 2017;12(2):341-347.
    MyJurnal
    Plasmasitoma ekstramedulari adalah komplikasi myeloma berbilang yang sangat
    jarang berlaku. Kami melaporkan kes seorang wanita berumur 56 tahun yang
    menghidap myeloma berbilang yang telah mengalami bengkak pada mata kiri. Ia
    menyebabkan bola mata beliau tersembul, luka pada kornea dan juga kemerosotan
    penglihatan. Biopsi tisu menunjukkan perebakan plasma sel neoplastik yang positif
    kepada CD138 dan rantai ringan Kappa yang menepati ciri-ciri plasmasitoma.
    Setelah melalui rawatan radio-kemoterapi, pembengkakan mata susut dengan
    ketara sekali namun kemerosotan penglihatan beliau tidak berubah.
    Matched MeSH terms: Multiple Myeloma
  3. Fulltext Fundamentals in the management of multiple myeloma
    Fadilah SA
    Med J Malaysia, 2010 Sep;65(3):231-9.
    PMID: 21939177
    Progress in our understanding of multiple myeloma and its treatment has resulted in a more tailored approach to patient management, with different therapeutics regimens for different patient populations. The decision to initiate therapy depends primarily on the presence of symptoms which has to balance the chance of tumor clearance and against the risks of treatment related mortality. Selection of appropriate initial treatment should be based primarily on patient's characteristics (biologic age, co-morbidities), the disease characteristics (tumor burden and genetic risk profile) and the expected toxicity profile of the different regimens. When treatment begins, in younger transplant eligible patients the goal is to achieve high quality responses with intensive therapies as the quality of response appears to be important surrogates for long-term outcome. In the majority of myeloma patients in whom intensive treatment is not an option due to advanced age and co-morbidities, treatment should emphasize on optimal disease control to obtain symptomatic relief and to maintain a satisfactory quality of life. The introduction of novel agents has substantially changed the treatment paradigm of this otherwise incurable disease. The utilization of these drugs has moved from relapse setting to the front line setting and has benefited all patient groups. Because of these rapid developments and many treatment options we need good quality clinical studies to guide clinical practice in the management of patients with multiple myeloma. This review presents an update on current concepts of diagnosis and treatment of patients with multiple myeloma and provides recommendations on tailored therapies with particular reference to the local practice. The information presented herein may be used by the health care providers caring for myeloma patients as a guideline to counsel patients to understand their disease and the treatment better.
    Matched MeSH terms: Multiple Myeloma/diagnosis; Multiple Myeloma/drug therapy; Multiple Myeloma/pathology; Multiple Myeloma/therapy*
  4. Fulltext Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma
    Soliman AM, Lin TS, Mahakkanukrauh P, Das S
    Int J Mol Sci, 2020 Oct 13;21(20).
    PMID: 33066062 DOI: 10.3390/ijms21207539
    Multiple myeloma (MM) is a cancerous bone disease characterized by malignant transformation of plasma cells in the bone marrow. MM is considered to be the second most common blood malignancy, with 20,000 new cases reported every year in the USA. Extensive research is currently enduring to validate diagnostic and therapeutic means to manage MM. microRNAs (miRNAs) were shown to be dysregulated in MM cases and to have a potential role in either progression or suppression of MM. Therefore, researchers investigated miRNAs levels in MM plasma cells and created tools to test their impact on tumor growth. In the present review, we discuss the most recently discovered miRNAs and their regulation in MM. Furthermore, we emphasized utilizing miRNAs as potential targets in the diagnosis, prognosis and treatment of MM, which can be useful for future clinical management.
    Matched MeSH terms: Multiple Myeloma/diagnosis; Multiple Myeloma/genetics*; Multiple Myeloma/metabolism; Multiple Myeloma/therapy
  5. Fulltext Tuberculosis of the skull mimicking multiple myeloma
    Pan KL, Zulkarnaen M
    Med J Malaysia, 2014 Aug;69(4):197-8.
    PMID: 25500853 MyJurnal
    There is a resurgence of tuberculosis globally but lesions affecting the skull are rare. Cases reported are of single, focal lesions as seen on plain x-rays. We report a 34 yearold patient with tuberculosis of the skull where multiple punched out lesions are seen, mimicking that of multiple myeloma.
    Matched MeSH terms: Multiple Myeloma
  6. Heavy/light chain assay in the monitoring of multiple myeloma
    Ting HY, Sthaneshwar P, Bee PC, Shanmugam H, Lim M
    Pathology, 2019 Aug;51(5):507-511.
    PMID: 31253381 DOI: 10.1016/j.pathol.2019.04.002
    Serum protein (SPE) and immunofixation electrophoresis (IFE) have been extensively validated for the routine use of identifying, characterising and quantifying monoclonal proteins. However, accurate quantitation of IgA monoclonal proteins can be difficult when they migrate in to the β fraction, due to co-migration with transferrin and complement components. The heavy/light chain (HLC) immunoassay is an additional tool for measuring intact immunoglobulin monoclonal proteins. Therefore, we aimed to examine the clinical utility of the HLC assay for the disease monitoring of IgG and IgA multiple myeloma (MM) patients. A total of 177 samples from 30 MM patients (21 IgG and 9 IgA) were analysed retrospectively with median number of six follow up samples per patient (range 3-13). Serum free light chains (sFLC) and HLC were quantified using Freelite and Hevylite immunoassays. Details of M-protein concentration, β-globulin levels, total immunoglobulin levels and disease treatment response were obtained from the laboratory and patient information system. Passing-Bablok regression analysis was performed to compare (i) M-protein quantification with involved HLC (iHLC) and (ii) total immunoglobulin with summated HLC pairs for each immunoglobulin type (e.g., IgGκ+IgGλ). For 127 IgG MM samples, IgG iHLC levels showed a good correlation with SPE quantification (iHLC y=0.96x+4.9; r=0.917) and summated HLC showed a good correlation with total IgG concentration (summated HLC y=0.94x+5.74; r=0.91). In total, 95/127 (75%) IgG MM follow-up samples had an abnormal HLC ratio and 122/127 (96%) had a positive SPE, probably due to the lower sensitivity of HLC assay in detecting clonality in patients with IgG MM. Consistent with this, one patient assigned a very good partial response by International Myeloma Working Group criteria would be assigned a complete response based on HLC measurements. For 50 IgA MM samples, 42/50 (84%) had an abnormal HLC ratio. Conversely, 50/50 (100%) of M-proteins showed β fraction migration and were difficult to accurately quantify by SPE. Therefore, M-protein concentration and iHLC did not correlate as well in IgA MM (y=1.9x-8.4; r=0.8) compared to IgG MM. However, there was good correlation between total IgA and summated IgA HLC (IgAκ+IgAλ y=1.35x-0.33; r=0.95). Of the 8/50 (16%) IgA samples with a normal HLC ratio, 6/8 (75%) were consistent with the disease status being in complete remission. Interestingly, in one IgA MM patient, SPE and IFE were negative, but the serum FLC ratio and involved FLC were highly abnormal, consistent with the presence of light chain escape. Our data suggest HLC measurements could add value to the current disease monitoring of MM patients. In IgG MM patients, the M-protein level correlated well with HLC values. The HLC assay complements the serum FLC assay and is especially useful for monitoring of IgA MM patients who display M-proteins migrating in the β region on SPE.
    Matched MeSH terms: Multiple Myeloma/blood*; Multiple Myeloma/diagnosis*; Multiple Myeloma/immunology
  7. Fulltext Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis
    Soliman AM, Das S, Teoh SL
    Int J Mol Sci, 2021 Jul 13;22(14).
    PMID: 34299097 DOI: 10.3390/ijms22147470
    Multiple myeloma (MM) is considered to be the second most common blood malignancy and it is characterized by abnormal proliferation and an accumulation of malignant plasma cells in the bone marrow. Although the currently utilized markers in the diagnosis and assessment of MM are showing promising results, the incidence and mortality rate of the disease are still high. Therefore, exploring and developing better diagnostic or prognostic biomarkers have drawn global interest. In the present review, we highlight some of the recently reported and investigated novel biomarkers that have great potentials as diagnostic and/or prognostic tools in MM. These biomarkers include angiogenic markers, miRNAs as well as proteomic and immunological biomarkers. Moreover, we present some of the advanced methodologies that could be utilized in the early and competent diagnosis of MM. The present review also focuses on understanding the molecular concepts and pathways involved in these biomarkers in order to validate and efficiently utilize them. The present review may also help in identifying areas of improvement for better diagnosis and superior outcomes of MM.
    Matched MeSH terms: Multiple Myeloma/genetics; Multiple Myeloma/pathology*; Multiple Myeloma/therapy
  8. Fulltext A rare occurrence of plasma cell myeloma with biclonal gammopathy
    Mardziah, M., Nurasyikin, Y., Rafeah, T., Dian, N., Yousuf, R., Suria, A.A.
    Medicine & Health, 2017;12(1):103-108.
    MyJurnal
    Plasma cell myeloma is known to cause expansion of a single clone of munoglobulin (Ig) which results in the secretion of a unique homogeneous monoclonal protein (M component). However, there are cases which reported that it can also cause production of two different clones of these monoclonal proteins. Although it is relatively very rare as the prevalence is only 2% of all plasma cell myeloma cases, the clinical features are said to be similar to monoclonal gammopathy. It is suggested that these biclonal gammopathy results from either one monoclonal cell clone in monoclonal gammopathy or two different monoclonal cell clones. Whichever the mechanism of the disease be, the response to treatment seems to be similar as compared to the monoclonal cases although some reports shows chemoresistant. Here, we report a rare case of plasma cell myeloma with IgG (lambda) and IgA (lambda) type of biclonal gammopathy, the clinical presentation, the haematological and biochemical markers as well as the response to the treatment.
    Keywords: biclonal gammopathy, M protein, plasma cell myeloma
    Matched MeSH terms: Multiple Myeloma
  9. A morphological and immunohistochemical study of plasma cell proliferative lesions
    Boo K, Cheng S
    Malays J Pathol, 1992 Jun;14(1):45-8.
    PMID: 1469918
    Monoclonal plasma cell proliferative diseases such as multiple myeloma and plasmacytoma can involve extramedullary sites at the time of first presentation, or subsequently in the course of the disease. Under such circumstances, they can mimic primary or metastatic carcinomas, neuroendocrine or neuroectodermal tumours and lymphomas, and the pathologist often has to resort to immunohistochemistry as an aid to diagnosis. We studied the morphology and immunohistochemical properties of 10 cases of previously confirmed monoclonal plasma cell proliferative lesions retrieved from the files of the Department of Pathology, University of Malaya. Serial 4u thick paraffin sections were stained with H&E, the Unna-Pappenheim technique for nucleic acid and a panel of antibodies using a standard immunoperoxidase technique. Light chain restriction was demonstrable in most of the cases. Seven (70%) showed kappa and 2 (20%) lambda light chain restriction. The remaining case was not stainable with most of the antibodies in the panel. The majority (80%) of cases showed accompanying IgG heavy chain in the cytoplasm, while 1 case had IgA. Seven (70%) showed membrane positivity with antibody to epithelial membrane antigen (EMA) and 7 (70%) cytoplasmic positivity with antibody to vimentin. This study enhances our awareness that neoplastic plasma cells can be positive for EMA and vimentin, and cautions us from misinterpreting these lesions as carcinomas or sarcomas. Notwithstanding that, immunohistochemical staining for kappa and lambda light chains can be helpful in differentiating monoclonal plasma cell proliferations from polyclonal ones.
    Matched MeSH terms: Multiple Myeloma/pathology*
  10. Fulltext The epidemiology of haematological cancers in Sarawak, Malaysia (1996 to 2015)
    Kuan JW, Su AT, Wahab M, Hamdan A, Hashim J, Kiyu A, et al.
    BMC Cancer, 2023 Jun 19;23(1):563.
    PMID: 37337159 DOI: 10.1186/s12885-023-10988-y
    BACKGROUND: Published epidemiological studies of haematological cancers are few. Hereby we present a 20-year epidemiological data of haematological cancers in Sarawak from a population-based cancer registry.

    METHODS: Haematological cancer cases with ICD-10 coded C81-C96 and ICD-O coded /3 diagnosed from 1996 to 2015 were retrieved from Sarawak Cancer Registry. Adult was defined as those 15 years and above. Incidence rate (IR) was calculated based on yearly Sarawak citizen population stratified to age, gender, and ethnic groups. Age-standardised IR (ASR) was calculated using Segi World Standard Population.

    RESULTS: A total of 3,947 cases were retrieved and analysed. ASR was 10 and male predominance (IR ratio 1.32, 95%CI 1.24,1.41). Haematological cancers generally had a U-shaped distribution with lowest IR at age 10-14 years and exponential increment from age 40 years onwards, except acute lymphoblastic leukaemia (ALL) with highest IR in paediatric 2.8 versus adult 0.5. There was a significant difference in ethnic and specific categories of haematological cancers, of which, in general, Bidayuh (IR ratio 1.13, 95%CI 1.00, 1.27) and Melanau (IR ratio 0.54, 95%CI 0.45, 0.65) had the highest and lowest ethnic-specific IR, respectively, in comparison to Malay. The ASR (non-Hodgkin lymphoma, acute myeloid leukaemia, ALL, chronic myeloid leukaemia, and plasma cell neoplasm) showed a decreasing trend over the 20 years, -2.09 in general, while Hodgkin lymphoma showed an increasing trend of + 2.80. There was crude rate difference between the 11 administrative divisions of Sarawak.

    CONCLUSIONS: This study provided the IR and ASR of haematological cancers in Sarawak for comparison to other regions of the world. Ethnic diversity in Sarawak resulted in significant differences in IR and ASR.

    Matched MeSH terms: Multiple Myeloma*
  11. Light chain multiple myeloma: an evaluation of its biochemical investigations
    Zahari Sham SY, C Thambiah S, Samsudin IN, Lim SM
    Malays J Pathol, 2017 Dec;39(3):311-315.
    PMID: 29279596 MyJurnal
    Multiple myeloma is a type of plasma cell dyscrasia, characterised by presence of paraprotein or monoclonal (M)-protein in serum or urine. The M-protein may consist of an intact immunoglobulin, the heavy chain only or the light chain only. The latter, designated as light chain multiple myeloma (LCMM) makes up almost 20% of myelomas. Clinical manifestation is often heralded by hypercalcaemia, renal impairment, normocytic normochromic anaemia and bone lesions, reflecting end-organ damage, collectively known as the acronym CRAB. In particular, free light chain nephrotoxicity accounts for the high prevalence of renal impairment seen in LCMM. This case illustrates a typical presentation of LCMM with focal discussion on its initial and diagnostic, as well as prognostic biochemical investigations.
    Matched MeSH terms: Multiple Myeloma/complications; Multiple Myeloma/immunology*; Multiple Myeloma/pathology
  12. Fulltext Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review
    McShane CM, Murray LJ, Landgren O, O'Rorke MA, Korde N, Kunzmann AT, et al.
    Cancer Epidemiol Biomarkers Prev, 2014 Feb;23(2):332-42.
    PMID: 24451437 DOI: 10.1158/1055-9965.EPI-13-0695
    BACKGROUND: Several observational studies have investigated autoimmune disease and subsequent risk of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Findings have been largely inconsistent and hindered by the rarity and heterogeneity of the autoimmune disorders investigated. A systematic review of the literature was undertaken to evaluate the strength of the evidence linking prior autoimmune disease and risk of MGUS/multiple myeloma.

    METHODS: A broad search strategy using key terms for MGUS, multiple myeloma, and 50 autoimmune diseases was used to search four electronic databases (PubMed, Medline, Embase, and Web of Science) from inception through November 2011.

    RESULTS: A total of 52 studies met the inclusion criteria, of which 32 were suitably comparable to perform a meta-analysis. "Any autoimmune disorder" was associated with an increased risk of both MGUS [n = 760 patients; pooled relative risk (RR) 1.42; 95% confidence interval (CI), 1.14-1.75] and multiple myeloma (n>2,530 patients; RR 1.13, 95% CI, 1.04-1.22). This risk was disease dependent with only pernicious anemia showing an increased risk of both MGUS (RR 1.67; 95% CI, 1.21-2.31) and multiple myeloma (RR 1.50; 95% CI, 1.25-1.80).

    CONCLUSIONS: Our findings, based on the largest number of autoimmune disorders and patients with MGUS/multiple myeloma reported to date, suggest that autoimmune diseases and/or their treatment may be important in the etiology of MGUS/multiple myeloma. The strong associations observed for pernicious anemia suggest that anemia seen in plasma cell dyscrasias may be of autoimmune origin.

    IMPACT: Underlying mechanisms of autoimmune diseases, general immune dysfunction, and/or treatment of autoimmune diseases may be important in the pathogenesis of MGUS/multiple myeloma.

    Matched MeSH terms: Multiple Myeloma/immunology*; Multiple Myeloma/epidemiology
  13. Fulltext Recurrent multiple myeloma presenting as a breast plasmacytoma
    Kalyani A, Rohaizak M, Cheong SK, Nor Aini U, Balasundaram V, Norlia A
    Med J Malaysia, 2010 Sep;65(3):227-8.
    PMID: 21939175
    We describe a patient with multiple myeloma, who initially responded to chemotherapy and went into remission. She presented 10 months later with a right breast lump which was confirmed by core biopsy to be a plasmacytoma. Further treatment with radiotherapy, thalidomide and later second line chemotherapy appeared unsuccessful and she showed rapid disease progression with rising paraproteins and new extramedullary plasmacytoma lesions in the forehead, supraclavicular region, nasopharynx, liver, spleen, pancreas and paraaortic lymph nodes.
    Matched MeSH terms: Multiple Myeloma/drug therapy; Multiple Myeloma/pathology*
  14. POEMS syndrome, osteosclerotic myeloma and Castleman's disease: a case report
    Bosco J, Pathmanathan R
    Aust N Z J Med, 1991 Aug;21(4):454-6.
    PMID: 1953537
    Peripheral neuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes are often the presenting features of the POEMS syndrome. Approximately 50% of these are associated with osteosclerotic myeloma, a rare variant of multiple myeloma and some with Castleman's disease, an unusual lympho-proliferative disorder. The underlying pathogenetic mechanisms have not been elucidated but amelioration of symptoms with the disappearance of the M-component suggests possible etiopathogenic mechanisms. We present a 40-year-old woman with manifestations of all three disorders.
    Matched MeSH terms: Multiple Myeloma/complications*; Multiple Myeloma/pathology
  15. Serum free light chains: diagnostic and prognostic value in multiple myeloma
    Sthaneshwar P, Nadarajan V, Maniam JA, Nordin N, Gin Gin G
    Clin Chem Lab Med, 2009;47(9):1101-7.
    PMID: 19728852 DOI: 10.1515/CCLM.2009.260
    Measurement of serum free light chains (FLCs) has recently become available for the diagnosis and monitoring of patients with plasma cell dyscrasias. The aim of this study was to investigate the performance of the serum FLC assay as a tumour marker by comparing FLC concentrations with serum protein electrophoresis (PE) results in the diagnosis of multiple myeloma (MM). In addition, we also evaluated the prognostic value of the baseline serum FLC ratio in patients with MM.
    Matched MeSH terms: Multiple Myeloma/diagnosis*; Multiple Myeloma/mortality
  16. Orbital multiple myeloma: a diagnostic challenge
    Tai E, Sim SK, Haron J, Wan Hitam WH
    BMJ Case Rep, 2017 Aug 07;2017.
    PMID: 28790098 DOI: 10.1136/bcr-2017-220895
    Orbital involvement in multiple myeloma is unusual. We describe the case of an 85-year-old woman who presented with right eye proptosis, reduced visual acuity and diplopia. Computed tomography showed a lobulated, enhancing soft tissue mass arising from the right greater wing of the sphenoid with intraconal, lacrimal gland and ocular muscle involvement. Histopathology revealed predominantly atypical plasma cells in a background of reactive lymphocytes, with monoclonality towards kappa light chain protein, suggestive of multiple myeloma. This case illustrates the diagnostic imaging challenge of orbital multiple myeloma.
    Matched MeSH terms: Multiple Myeloma/diagnosis*; Multiple Myeloma/pathology
  17. Multiple myeloma masquerading as panuveitis in a middle-aged woman
    Yew YC, Nurul-Fatin FS, Norazita AT
    Med J Malaysia, 2017 12;72(6):376-377.
    PMID: 29308780 MyJurnal
    Panuveitis secondary to masquerade syndrome is uncommon. A middle-aged woman presented to the ophthalmology clinic with panuveitis associated with anaemia, joint pain, and renal impairment. An incidental finding of a lytic lesion over her left scapula following a chest x-ray prompted further skeletal survey and revealed further lytic lesions over the skull and pelvic bone. Bone marrow aspiration was performed and this confirmed the diagnosis of multiple myeloma. Her left eye vision and intraocular inflammation improved after commencement of chemotherapy. A detailed history is important to elucidate the aetiology of masquerade syndrome and to prevent any delayed diagnosis of underlying malignancy.
    Matched MeSH terms: Multiple Myeloma/diagnosis*; Multiple Myeloma/drug therapy
  18. Recurrence of multiple myeloma with soft tissue plasmacytoma presenting as unilateral proptosis
    Pan SW, Wan Hitam WH, Mohd Noor RA, Bhavaraju VM
    Orbit, 2011 Mar;30(2):105-7.
    PMID: 21322793 DOI: 10.3109/01676830.2010.546553
    To describe a rare case of soft tissue plasmacytoma of the orbit presenting with proptosis.
    Matched MeSH terms: Multiple Myeloma/diagnosis*; Multiple Myeloma/radiotherapy
  19. Fulltext Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: A preliminary study
    Bong IP, Ng CC, Fakiruddin SK, Lim MN, Zakaria Z
    Bosn J Basic Med Sci, 2016 Nov 10;16(4):268-275.
    PMID: 27754828 DOI: 10.17305/bjbms.2016.1568
    Multiple myeloma (MM) is a malignancy of B lymphocytes or plasma cells. Our array-based comparative genomic hybridization findings revealed chromosomal gains at 7q22.3 and 1q42.3, where nicotinamide (NAM) phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) genes are localized, respectively. This led us to further study the functions of these genes in myeloma cells. NAMPT is a key enzyme involved in nicotinamide adenine dinucleotide salvage pathway, and it is frequently overexpressed in human cancers. In contrast, little is known about the function of LYST in cancer. The expression of LYST is shown to affect lysosomal size, granule size, and autophagy in human cells. In this study, the effects of small interfering RNA (siRNA)-mediated silencing of NAMPT and LYST on cell proliferation and apoptosis were evaluated in RPMI 8226 myeloma cells. Transfection efficiencies were determined by quantitative real time reverse transcriptase PCR. Cell proliferation was determined using MTT assay, while apoptosis was analyzed with flow cytometry using Annexin V-fluorescein isothiocyanate/propidium iodide assay. The NAMPT protein expression in siRNA-treated cells was estimated by enzyme-linked immunosorbent assay. Our results showed that NAMPT and LYST were successfully knockdown by siRNA transfection (p < 0.05). NAMPT or LYST gene silencing significantly inhibited cell proliferation and induced apoptosis in RPMI 8226 cells (p < 0.05). Silencing of NAMPT gene also decreased NAMPT protein levels (p < 0.01). Our study demonstrated that NAMPT and LYST play pivotal roles in the molecular pathogenesis of MM. This is the first report describing the possible functions of LYST in myelomagenesis and its potential role as a therapeutic target in MM.
    Matched MeSH terms: Multiple Myeloma/genetics*; Multiple Myeloma/therapy*
  20. Fulltext Myeloma kidney – a treatable yet often forgotten disease
    Lim, Christopher Thiam Seong, Fuah, Kar Wah, Khoo, Yoong Khean
    Malaysian Journal of Medicine and Health Sciences, 2017;13(2):63-65.
    MyJurnal
    Multiple myeloma is a blood dyscrasias that accounts of almost 10% of all hematological malignancy. The presentation of myeloma kidney is highly variable and it often presents as renal insufficiency, renal tubular dysfunction and proteinuria of various types. In Malaysia the true incidence of myeloma kidney is unknown. Often the diagnosis of myeloma kidney was missed out despite the patient has sought medical treatment early. A high index of suspicion is required when the middle to elderly age patients present with unexplained renal impairment and enlarged kidneys. We present here the presentation of a rare subtype of myeloma in a relatively young patient whereby the patient presented with nephrotic syndrome and aoztemia.
    Matched MeSH terms: Multiple Myeloma
Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links